Facebook
Twitter
LinkedIn
Forward
Seizure Clusters in the Real World: The Call to Arms
Overview
Treatment standards for neurologists and other clinicians caring for patients with epilepsy with emphasis on understanding epilepsy epidemiology, SUDEP and ILAE Classification updates, and therapeutic strategies.
Learning Objectives
After completing this educational activity, you should be able to:
- Educate patients who are at risk for seizure clusters about rescue medications and emergency plans
- Provide rescue treatment for seizure clusters that patients are inclined to use
Target Audience
Neurologists, neurology NPs and PAs, and other treaters of patients with epilepsy; patients with epilepsy and their caregivers
Program Description
Join Drs. Cascino and Lundstrom of the Mayo Clinic in Rochester, MN for the first of a two-part video series centered on seizure clusters in epilepsy. In this installment, participants can learn more about sudden unexpected death in epilepsy (SUDEP), the different types of epilepsy as classified by the International League Against Epilepsy (ILAE) guidelines, and the medications available for focal and generalized seizures. This opening segment also covers current unmet therapeutic needs for patients with seizures and the advantages associated with newer therapeutic options. To reinforce the need for newer medications and better standards of care, this video incorporates the lived experiences of Julie: a mother and caregiver to her epileptic daughter, Christina.
Patient Education Tool
Share this video with patients with epilepsy and their care partners to educate on the importance of a seizure action plan
Part of the series: Empowering Patients Living with Epilepsy with Rescue Treatment and Emergency Plans
You may also be interested in
Support Statement
Supported by an educational grant from Neurelis, Inc.
Learning Objective
After completing this educational activity, you should be able to:
- Educate patients who are at risk for seizure clusters about rescue medications and emergency plans
- Provide rescue treatment for seizure clusters that patients are inclined to use
Release, Review, and Expiration Dates
This CME activity was published in March 2023 and is eligible for AMA PRA Category 1 Credit™ through March 31, 2024.
Statement of Need and Purpose
Seizure clusters take a toll on patients’ emotional wellbeing, work, and quality of life and are associated with increased utilization of emergency departments. However, rescue treatment options have been limited; intravenous, intramuscular, and rectal options are impractical and often rejected by patients. Clinicians have often not documented providing any rescue treatment, and when emergency plans were recommended, patients have often not followed clinicians’ recommendations.
With the advent of nasal spray formulations of seizure rescue treatment, clinicians can offer an option that is easily used. Clinicians need education about identifying patients at risk for seizure clusters, educating them about rescue medication options, and making formal action plans with patients and their families.
Unlabeled and Investigational Usage
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.
No endorsement of unapproved products or uses is made or implied by coverage of these products or uses.
Please refer to the official prescribing information for each product for discussion of approved indicators, contraindications and warnings.
Review Process
The faculty members agreed to provide a balanced and evidence-based presentation and discussed the topics and CME objectives during the planning sessions. The faculty’s submitted content was validated by CME Institute staff, and the activity was evaluated for accuracy, use of evidence, and fair balance by the Chair and a peer reviewer who is without conflict of interest.
The opinions expressed herein are those of the faculty and do not necessarily reflect the opinions of the CME provider and publisher or the commercial supporter.
© Copyright 2023 Physicians Postgraduate Press, Inc.
Faculty Affiliation
|
|
Financial Disclosure
The CME Institute adheres to the Standards for Integrity and Independence in Accredited Continuing Education of the Accreditation Council for Continuing Medical Education (ACCME). Any individuals in a position to control the content of a continuing education activity, including faculty, content developers, reviewers, staff, and others, are required to disclose to learners the presence or absence of any relevant financial relationships with an ACCME-defined ineligible company within the preceding 24 months of the activity. The ACCME defines an “ineligible company” as one whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
The CME Institute has mitigated all relevant conflicts of interest prior to the commencement of the activity. None of the individuals involved in the content have relevant financial relationships with ineligible companies except the following:
Dr Cascino has received research Support from Longboard Pharmaceuticals, Marinus, and Zogenix; has received Royalties from Wiley-Blackwell and Springer; has received other financial support as Associate Editor of Epilepsia and Wiley. Dr. Cascino previously had stock options in Nevro Corporation, this relationship has ended; previously received research support from Neurelis, Human Epilepsy Project, GW Research Ltd, UCB Biopharma, these relationships have ended; has previously received other financial support from Wolters Kluwer and Neurology, these relationships have ended.
Dr Lundstrom has received research support from Medtronic EPAS, NeuroPace RESPONSE, Neuroelectrics tDCS for Epilepsy; has received consulting fees from Epiminder, Medtronic, Neuropace Philips Neuro; and has received other financial support from Cadence Neuroscience Inc.
Michael R. Page, PharmD, RPh
Independent Medical Director/Medical Writer
Plainsboro, New Jersey
Dr. Page is a consultant for BioCentric, Inc. and American Medical Communications, Inc.
None of the other planners, reviewers, and CME Institute staff for this educational activity have relevant financial relationships with ineligible companies to disclose. All relevant financial relationships have been mitigated.
Accreditation Statement
The CME Institute of Physicians Postgraduate Press, Inc., is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Credit Designation
The CME Institute of Physicians Postgraduate Press, Inc., designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Note: The American Nurses Credentialing Center (ANCC) and the American Academy of Physician Assistants (AAPA) accept certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.
To obtain credit for this activity, study the material and complete the CME Posttest and Evaluation.
Available Credit
- 0.50 AMA PRA Category 1 Credit™
- 0.50 Participation